Around the Practice: CAR-T Referral Process: Insights from MSKCC

home / around-the-practice / around-the-practice-car-t-referral-process-insights-from-mskcc

Saad Usmani, MD, MBA; Carlyn Rose Tan, MD; Sham Mailankody, MBBS, and Sridevi Rajeeve, MD, examine evolving chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, discussing recent clinical trial data for cilta-cel and ide-cel, comparing study outcomes, evaluating institutional implementation factors, and assessing patient eligibility criteria for optimal therapy selection in earlier treatment lines.

4 experts are featured in this series.

EP. 1: Highlighted Data Review of CAR-T in Early R/R MM

Saad Z. Usmani, MD, MBA, FACP;Carlyn Rose Tan, MD ;Sham Mailankody, MBBS ;Sridevi Rajeeve, MD
December 20th 2024

Panelists discuss how early-line chimeric antigen receptor T-cell therapy studies, including recent data from trials of cilta-cel (Popat et al) and ide-cel (Ailawadhi et al), are showing promising results in patients with relapsed/refractory multiple myeloma, suggesting potential benefits of moving these treatments into earlier therapeutic settings.

4 experts are featured in this series.

EP. 2: Expert Insights: Distinguishing between CARTITUDE-4 vs. KarMMa-3 Trials

Saad Z. Usmani, MD, MBA, FACP;Carlyn Rose Tan, MD ;Sham Mailankody, MBBS ;Sridevi Rajeeve, MD
January 3rd 2025

Panelists discuss how the CARTITUDE-4 and KarMMa-3 trials differ in their patient populations, study designs, and outcomes, providing crucial insights for clinicians choosing between cilta-cel and ide-cel chimeric antigen receptor T-cell therapies in relapsed/refractory multiple myeloma.